Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Day One Biopharmaceuticals
395 Oyster Point Blvd, Suite 217
South San Francisco, CA 94080
Phone: 650-484-0899

Inspired by children with cancer, Day One Biopharmaceuticals creatively and intentionally develops promising new therapies that change the outcome for people of all ages living with cancer. Day One\'s first announced program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop emerging cancer treatments that can help both children and adults living with cancer. Through Day One and its collaborators, cancer drug development comes of age.

Key Contact
Jeremy Bender
Funding Events

05/21/20 $60,000,000 Series A Access Industries
Atlas Venture
Canaan Partners
02/11/21 $130,000,000 Series B Access Biotechnology
Atlas Venture
Boxer Capital
BVF Partners
Canaan Partners
Franklin Templeton
Janus Henderson Investors
Perceptive Advisors
RA Capital Management
T. Rowe Price Associates
Viking Global Investors

Featured Reading